Key facts
- It has raised $42.0M across 1 recorded rounds; the latest was Seed Round ($507K) in May 2024.
- HavaH Therapeutics has filed 1 Form D with the SEC, most recently May 2024 ($507K sold to 14 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for HavaH Therapeutics
Funding rounds
1 roundsAbout HavaH Therapeutics
Developer of androgen therapies intended for curing breast disease by utilizing the innate breast tissue. The company's therapy delivers a unique androgen product to effect a beneficial tissue-specific alteration in estrogen androgen ratio and reduce breast tissue autoimmune inflammation, enabling women with androgenic products for women, initially targeting rare breast disease where autoimmunity is the underlying mechanism of the pathogenesis.
- Sector
- Healthcare
- HQ
- North Adelaide, Australia
- Founded
- 2005
- Employees
- 3
- Website
- havahtx.com/
- Ownership
- Privately Held (backing)
HavaH Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in HavaH Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on HavaH Therapeutics in its N-PORT filings yet. We sweep new filings monthly.